250 related articles for article (PubMed ID: 36295105)
1. Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab.
Mitroi GG; Stoica LE; Mitroi GF; Mitroi MR; Tutunaru CV; Ică OM; Ianoși LS
Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295105
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
4. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report.
Akhtar NH; Khosravi-Hafshejani T; Akhtar D; Dhadwal G; Kanani A
Allergy Asthma Clin Immunol; 2022 Feb; 18(1):9. PubMed ID: 35115035
[TBL] [Abstract][Full Text] [Related]
5. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature.
Lobo Y; Lee RC; Spelman L
Case Rep Dermatol; 2021; 13(2):248-256. PubMed ID: 34177514
[TBL] [Abstract][Full Text] [Related]
6. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
Francuzik W; Alexiou A; Worm M
Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
[No Abstract] [Full Text] [Related]
7. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer.
Tanczosova M; Hugo J; Gkalpakiotis S
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769838
[TBL] [Abstract][Full Text] [Related]
9. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
11. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults.
Xu X; Zheng Y; Zhang X; He Y; Li C
Oncotarget; 2017 Dec; 8(65):108480-108491. PubMed ID: 29312544
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
Katoh N; Kataoka Y; Saeki H; Hide M; Kabashima K; Etoh T; Igarashi A; Imafuku S; Kawashima M; Ohtsuki M; Fujita H; Arima K; Takagi H; Chen Z; Shumel B; Ardeleanu M
Br J Dermatol; 2020 Jul; 183(1):39-51. PubMed ID: 31564057
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases.
Foti C; Romita P; Ambrogio F; Manno C; Filotico R; Cassano N; Vena GA; De Marco A; Cazzato G; Mennuni BG
Life (Basel); 2022 Nov; 12(12):. PubMed ID: 36556367
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
[TBL] [Abstract][Full Text] [Related]
17. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.
Nakazaki K; Yoshida M; Masamoto Y; Shinozaki-Ushiku A; Ikemura M; Hisamoto T; Yasunaga M; Sato S; Kurokawa M
Int J Hematol; 2022 Sep; 116(3):446-452. PubMed ID: 35355217
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
20. Pustular Psoriasis in a Patient Treated with Dupilumab for Atopic Dermatitis: A Case Report.
Liu L; Chen J; Tang K; Li F; Li S; Ding X
Clin Cosmet Investig Dermatol; 2023; 16():2217-2221. PubMed ID: 37601418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
